Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hammerer

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Urologia Internationalis|January 1, 1988
Treatment of acute cellular rejection in renal transplantation patients on ciclosporin with antithymocyte globulinR Arndt, P Hammerer, E Huland, et al.
Human Pathology|May 1, 1994
Frequency and distribution of numerical chromosomal aberrations in prostatic cancerR P Henke, E Krüger, N Ayhan, et al.
Der Urologe. Ausg. A|May 1, 1998
[Development of tumor selection based on pathological stage in clinically localized prostate carcinoma]J Noldus, M Graefen, P Hammerer, et al.
Anticancer Research|May 1, 2001
The expression of angiopoietins and their receptor Tie-2 in human prostate carcinomaJ H Wurmbach, P Hammerer, S Sevinc, et al.
Virchows Archiv. A, Pathological Anatomy and Histopathology|January 1, 1993
Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kineticsR P Henke, E Krüger, N Ayhan, et al.
Der Urologe. Ausg. A|May 1, 1998
[Plasma TGF-beta1 concentrations in patients with prostate carcinoma or benign prostatic hyperplasia]I Lange, P Hammerer, C Knabbe, et al.
The Journal of Urology|November 20, 1997
Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasiaA Haese, M Graefen, J Noldus, et al.
The Journal of Urology|March 19, 1999
Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomyA Haese, E Huland, M Graefen, et al.
The Journal of Urology|May 23, 1998
The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancerJ Noldus, M Graefen, E Huland, et al.
European Urology|September 4, 1999
Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumorsH Hilz, J Noldus, P Hammerer, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Urologia Internationalis|January 1, 1988
Treatment of acute cellular rejection in renal transplantation patients on ciclosporin with antithymocyte globulinR Arndt, P Hammerer, E Huland, et al.
Human Pathology|May 1, 1994
Frequency and distribution of numerical chromosomal aberrations in prostatic cancerR P Henke, E Krüger, N Ayhan, et al.
Der Urologe. Ausg. A|May 1, 1998
[Development of tumor selection based on pathological stage in clinically localized prostate carcinoma]J Noldus, M Graefen, P Hammerer, et al.
Anticancer Research|May 1, 2001
The expression of angiopoietins and their receptor Tie-2 in human prostate carcinomaJ H Wurmbach, P Hammerer, S Sevinc, et al.
Virchows Archiv. A, Pathological Anatomy and Histopathology|January 1, 1993
Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kineticsR P Henke, E Krüger, N Ayhan, et al.
Der Urologe. Ausg. A|May 1, 1998
[Plasma TGF-beta1 concentrations in patients with prostate carcinoma or benign prostatic hyperplasia]I Lange, P Hammerer, C Knabbe, et al.
The Journal of Urology|November 20, 1997
Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasiaA Haese, M Graefen, J Noldus, et al.
The Journal of Urology|March 19, 1999
Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomyA Haese, E Huland, M Graefen, et al.
The Journal of Urology|May 23, 1998
The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancerJ Noldus, M Graefen, E Huland, et al.
European Urology|September 4, 1999
Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumorsH Hilz, J Noldus, P Hammerer, et al.
Pageof 9